Immunogenicity and reactogenicity of primary immunization with a novel combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine coadministered with a diphtheria-tetanus- acellular pertussis-hepatitis B-inactivated poliovirus vaccine at 2, 4 and 6 months

Pediatric Infectious Disease Journal

Volumn 26, Issue 1, 2007, Pages 1-7

  Tejedor, Juan C ^a   Moro, Manuel ^b   Ruiz Contreras, Jesús ^c   Castro, Javier ^c   Gómez Campderá, José Antonio ^d   Navarro, María Luisa ^d   Merino, José Manuel ^e   Martín Ancel, Ana ^f   Roca, Joan ^g   García Del Rí, Manuel ^h   Jurado, Antonio ^h   Díez Delgado, Francisco Javier ⁱ   Omeñaca, Félix ^j   García Sicilia, José ^j   Boceta, Reyes ^k,l   García Corbeira, Pilar ^k,l   Collard, Alix ^k,l   Boutriau, Dominique ^k,l   Schuerman, Lode ^k,l   Jacquet, Jeanne Marie ^k,l  

^a HOSPITAL DE MÓSTOLES   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^f HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^g HOSPITAL SANT JOAN DE DÉU   (Spain)

^h HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

ⁱ HOSPITAL TORRECÁRDENAS   (Spain)

^j HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^k GLAXOSMITHKLINE   (Spain)

^l GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

more..

Author keywords

Coadministration; DTPa HBV IPV vaccine; Haemophilus influenzae type b conjugate vaccine; Meningococcal C conjugate vaccine; Primary immunization

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA TETANUS ACELLULAR PERTUSSIS HEPATITIS B INACTIVATED POLIOVIRUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B AND NEISSERIA MENINGITIDIS C TETANUS TOXOID CONJUGATE VACCINE; INACTIVATED VACCINE; MENINGOCCAL TETANUS TOXOID CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; NEISVAC C; UNCLASSIFIED DRUG; VACCINE;

ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DRUG CONJUGATION; FEMALE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA; MALE; MENINGITIS; MULTICENTER STUDY; NEWBORN; PERTUSSIS; PHASE 2 CLINICAL TRIAL; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TETANUS; UNSPECIFIED SIDE EFFECT;

FEMALE; HAEMOPHILUS VACCINES; HUMANS; INFANT, NEWBORN; MALE; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP C; POLYSACCHARIDES, BACTERIAL; VACCINES, COMBINED;

EID: 33846012561     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000247070.60063.09     Document Type: Article

References (22)

1. Atkinson WL, Pickering LK, Schwartz B, et al. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Recomm Rep. 2002;51:1-35.
2. EUvac.net; A surveillance community network for vaccine preventable infectious diseases. Available at: www.euvac.net/graphics/html/EUVAC/index.html. Childhood vaccination schedules. Accessed August 17, 2005.
3. Snape MD, Pollard AJ. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis. 2005;5:21-30.
4. Cano R, Larrauri A, Mateo S, et al. Impact of the meningococcal C conjugate vaccine in Spain: An epidemiological and microbiological decision. Eurosurveillance. 2004;9:7-8. Available at: http://eurosurveilance. org/em/v09n07/0907-223asp.
5. Carion F, Hanquet G, Collard JM. Epidemiology of meningococcal C disease in Belgium one year after a mass immunization campaign. In: 7th meeting of the European Monitoring Group on Meningococci; Lanzarote, Spain; September 24-27, 2003:62.
6. Menon A, Cafferkey M, Murphy K, et al. The epidemiology of invasive meningococcal disease and the impact of the meningococcal C vaccine in Ireland. In: 7th meeting of the European Monitoring Group on Meningococci; Lanzarote, Spain; September 24-27, 2003:65.
7. Miller E, Salisbury D, Ramsay ME. Planning, registration, and implementation of an immunization campaign against meningococcal serogroup C disease in the UK: A success story. Vaccine. 2002;20(suppl 1):S58-67.
8. Tejedor J-C, Omeñaca F, Garcia-Sicilia J, et al. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine co-administered with a meningococcal C conjugate vaccine. Pediatr Infect Dis J. 2004;23:1109-1115.
9. Tejedor JC, Moro M, Mariscal E, et al. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type B vaccine co-administered with two doses of a meningococcal C conjugate vaccine. Pediatr Infect Dis J. 2006;25:713-720.
10. Arístegui J, Dal-Ré R, Díez-Delgado J, et al. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Vaccine. 2003;21:3593-3600.
11. Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: Reevaluation of correlates of protection. Infect Immun. 2001;69:1568-1573.
12. Borrow R, Goldblatt D, Finn A, et al. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United Kingdom. Infect Immun. 2003;71:5549-5555.
13. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003;10:780-786.
14. Trotter C, Borrow R, Andrews N, Miller E. Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine. 2003;21:1094-1098.
15. Santos GF, Deck RR, Donnelly J, Blackwelder W, Granhoff DM. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol. 2001;8:616-623.
16. Vidor E, Hoffenbach A, Fletcher MA. Haemophilus influenzae type b vaccine: Reconstitution of lyophilised PRP-T vaccine with a paediatric pertussis-containing combination vaccine, or a change in the primary series immunization schedule, may modify the serum anti-PRP responses. Curr Res Med Opin. 2001;17:197-209.
17. Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist CA. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet. 1999;354:2063-2068.
18. NeisVac-C Summary of Product Characteristics. Available at: http:// emc.medicines.org.uk/.
19. Miller E, Southern J, Kitchin N, et al. Interaction between different meningococcal C conjugate vaccines and the Hib component of concomitantly administered diphtheria/tetanus/pertussis/Hib vaccines with either whole cell or acellular pertussis antigens [Abstract 169]. Presented at the 21st Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); Taormina, Italy; April 9-11, 2003.
20. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364:365-367.
21. Larrauri A, Cano R, García M, deMateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine. 2005;23:4097-4100.
22. Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol. 2005;162:89-100.